Digene HPV DNA Pap Test Impact Should Be Assessed Postmarket – Panel
This article was originally published in The Gray Sheet
Executive Summary
Digene's HPV DNA Pap test should be approved as a primary screen for cervical cancer contingent upon clarification of clinical utility using existing data, FDA's Microbiology Devices Panel concluded in a 6-2 vote March 8 in Gaithersburg, Maryland
You may also be interested in...
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
Digene Still Expecting HPV DNA Pap Test Primary Screen Approval By 2003
Digene will re-analyze pivotal study data to demonstrate clinical utility of its HPV DNA Pap test as a primary screen for cervical cancer in response to an FDA request for additional information